Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Excler

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Vaccine|September 17, 2025
Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and childrenRejwana Haque Pial, Maria Rosario Capeding, Birkneh Tilahun Tadesse, et al.
Vaccine|December 31, 2021
A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, BangladeshFahima Chowdhury, Afroza Akter, Taufiqur Rahman Bhuiyan, et al.
Plos Pathogens|December 16, 2014
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAlexandra Schuetz, Claire Deleage, Irini Sereti, et al.
Journal of Medical Virology|October 28, 2021
Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international databaseMin Seo Kim, Se Yong Jung, Jong Gyun Ahn, et al.
Human Vaccines & Immunotherapeutics|May 29, 2012
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse eventsClaudia Schmidt, Carol Smith, Burc Barin, et al.
Plos Pathogens|May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall responseLaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Journal of Virology|November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and PotencyDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Vaccine|September 17, 2025
Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and childrenRejwana Haque Pial, Maria Rosario Capeding, Birkneh Tilahun Tadesse, et al.
Vaccine|December 31, 2021
A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, BangladeshFahima Chowdhury, Afroza Akter, Taufiqur Rahman Bhuiyan, et al.
Plos Pathogens|December 16, 2014
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAlexandra Schuetz, Claire Deleage, Irini Sereti, et al.
Journal of Medical Virology|October 28, 2021
Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international databaseMin Seo Kim, Se Yong Jung, Jong Gyun Ahn, et al.
Human Vaccines & Immunotherapeutics|May 29, 2012
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse eventsClaudia Schmidt, Carol Smith, Burc Barin, et al.
Plos Pathogens|May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall responseLaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Journal of Virology|November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and PotencyDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Pageof 12